share_log

AbbVie | 8-K: AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense

AbbVie | 8-K: AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense

艾伯维公司 | 8-K:艾伯维公司指导方针包括收购知识产权研发和里程碑支出的影响
美股SEC公告 ·  07/03 14:10

Moomoo AI 已提取核心信息

AbbVie Inc. has released a preliminary report on July 3, 2024, detailing the expected financial results for the second quarter of 2024. The report includes an acquired IPR&D and milestones expense of $937 million on a pre-tax basis, which is anticipated to negatively impact GAAP and non-GAAP diluted earnings per share by $0.52. The results for the quarter ending June 30, 2024, are not yet finalized and are subject to financial statement closing procedures. AbbVie has updated its full-year 2024 adjusted diluted earnings per share guidance to a range of $10.61 to $10.81, including the impact of the second quarter's acquired IPR&D and milestones expense. The second quarter's adjusted diluted earnings per share guidance is set between $2.53 and $2.57. The company has previously announced that its adjusted diluted earnings per share guidance for 2024, announced on April 26, 2024, did not include the impact of any acquired IPR&D and milestones expense beyond the first quarter. AbbVie's forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected.
AbbVie Inc. has released a preliminary report on July 3, 2024, detailing the expected financial results for the second quarter of 2024. The report includes an acquired IPR&D and milestones expense of $937 million on a pre-tax basis, which is anticipated to negatively impact GAAP and non-GAAP diluted earnings per share by $0.52. The results for the quarter ending June 30, 2024, are not yet finalized and are subject to financial statement closing procedures. AbbVie has updated its full-year 2024 adjusted diluted earnings per share guidance to a range of $10.61 to $10.81, including the impact of the second quarter's acquired IPR&D and milestones expense. The second quarter's adjusted diluted earnings per share guidance is set between $2.53 and $2.57. The company has previously announced that its adjusted diluted earnings per share guidance for 2024, announced on April 26, 2024, did not include the impact of any acquired IPR&D and milestones expense beyond the first quarter. AbbVie's forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected.
艾伯维公司于2024年7月3日发布了一份初步报告,详细说明了2024年第二季度的预期财务业绩。报告包括一项税前的知识产权研发和里程碑费用93700万美元,预计将对GAAP和非GAAP稀释每股收益产生0.52美元的负面影响。截至2024年6月30日的季度业绩尚未最终确定,且需进行财务报表结算程序。艾伯维公司已将其2024年全年调整后稀释每股收益指南更新至10.61至10.81美元区间,已包括第二季度知识产权研发和里程碑费用的影响。第二季度的调整后稀释每股收益指南设定在2.53至2.57美元之间。该公司此前已宣布,其于2024年4月26日宣布的2024年调整后稀释每股收益指南不包括除第一季度之外的任何税前知识产权研发和里程碑费用的影响。艾伯维公司的前瞻性声明受到风险和不确定性的影响,可能导致实际结果与预期有所不同。
艾伯维公司于2024年7月3日发布了一份初步报告,详细说明了2024年第二季度的预期财务业绩。报告包括一项税前的知识产权研发和里程碑费用93700万美元,预计将对GAAP和非GAAP稀释每股收益产生0.52美元的负面影响。截至2024年6月30日的季度业绩尚未最终确定,且需进行财务报表结算程序。艾伯维公司已将其2024年全年调整后稀释每股收益指南更新至10.61至10.81美元区间,已包括第二季度知识产权研发和里程碑费用的影响。第二季度的调整后稀释每股收益指南设定在2.53至2.57美元之间。该公司此前已宣布,其于2024年4月26日宣布的2024年调整后稀释每股收益指南不包括除第一季度之外的任何税前知识产权研发和里程碑费用的影响。艾伯维公司的前瞻性声明受到风险和不确定性的影响,可能导致实际结果与预期有所不同。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息